209 related articles for article (PubMed ID: 16943528)
1. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
Guadagnolo BA; Punglia RS; Kuntz KM; Mauch PM; Ng AK
J Clin Oncol; 2006 Sep; 24(25):4116-22. PubMed ID: 16943528
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
3. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis.
Das P; Ng AK; Earle CC; Mauch PM; Kuntz KM
Ann Oncol; 2006 May; 17(5):785-93. PubMed ID: 16500905
[TBL] [Abstract][Full Text] [Related]
4. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
[TBL] [Abstract][Full Text] [Related]
6. Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission.
Pingali SR; Jewell SW; Havlat L; Bast MA; Thompson JR; Eastwood DC; Bartlett NL; Armitage JO; Wagner-Johnston ND; Vose JM; Fenske TS
Cancer; 2014 Jul; 120(14):2122-9. PubMed ID: 24711253
[TBL] [Abstract][Full Text] [Related]
7. Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis.
Ng AK; Weeks JC; Mauch PM; Kuntz KM
J Clin Oncol; 1999 Jan; 17(1):241-52. PubMed ID: 10458239
[TBL] [Abstract][Full Text] [Related]
8. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
9. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
[TBL] [Abstract][Full Text] [Related]
10. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
11. Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease.
Ng AK; Kuntz KM; Mauch PM; Weeks JC
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):979-89. PubMed ID: 11429226
[TBL] [Abstract][Full Text] [Related]
12. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
13. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
[TBL] [Abstract][Full Text] [Related]
15. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
Basaran G; Agaoglu F; Basaran M
J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
[No Abstract] [Full Text] [Related]
18. Spontaneous regression of Hodgkin's disease: two case reports and a review of the literature.
Mangel J; Barth D; Berinstein NL; Imrie KR
Hematology; 2003 Jun; 8(3):191-6. PubMed ID: 12745644
[TBL] [Abstract][Full Text] [Related]
19. [Our experiences in treating patients with Hodgkin disease in the last decade].
Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
[TBL] [Abstract][Full Text] [Related]
20. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
